Infant Bacterial Therapeutics AB (publ) (BST:9IB)

Market Cap	77.93M +8.3%
Revenue (ttm)	n/a
Net Income	-7.40M
EPS	-0.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.16
Previous Close	6.15
Day's Range	5.94 - 6.16
52-Week Range	3.83 - 7.46
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About BST:9IB

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 6
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: 9IB

Financial Performance

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 31, 2026

Data Sources Report a data error